ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.07 USD | -0.70% |
|
-1.95% | -45.48% |
Financials (USD)
| Sales 2024 * | 968M | Sales 2025 * | 1.09B | Capitalization | 2.81B |
|---|---|---|---|---|---|
| Net income 2024 * | 113M | Net income 2025 * | 224M | EV / Sales 2024 * | 2.28 x |
| Net cash position 2024 * | 606M | Net cash position 2025 * | 863M | EV / Sales 2025 * | 1.79 x |
| P/E ratio 2024 * |
26.5
x | P/E ratio 2025 * |
13
x | Employees | 598 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on ACADIA Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | -0.70% | ||
| 1 week | -1.95% | ||
| Current month | -7.68% | ||
| 1 month | -8.81% | ||
| 3 months | -38.13% | ||
| 6 months | -26.45% | ||
| Current year | -45.48% |
1 week
16.60
17.35
1 month
16.6019.00
Current year
16.6031.82
1 year
16.6033.99
3 years
12.2433.99
5 years
12.2458.72
10 years
12.2458.72
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Sanjeev Pathak
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.73% | 1 M€ | 0.00% | - | |
| 1.24% | 16 M€ | -9.75% | ||
| 0.26% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 17.07 | -0.70% | 988,365 |
| 24-04-17 | 17.19 | +0.64% | 1,027,814 |
| 24-04-16 | 17.08 | +1.12% | 978,294 |
| 24-04-15 | 16.89 | -1.46% | 1,112,106 |
| 24-04-12 | 17.14 | -1.55% | 1,296,092 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
17.07
USD
Average target price
29.17
USD
Spread / Average Target
+70.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.48% | 2.81B | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- ACAD Stock
